Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Trial Profile

Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milciclib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Tiziana Life Sciences
  • Most Recent Events

    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 14 May 2020 According to a Tiziana Lifesciences media release, the trial successfully met the primary endpoint that oral treatment with Milciclib was well tolerated with manageable toxicities and no recorded drug related deaths.
    • 14 May 2020 According to a Tiziana Lifesciences media release, the company today announced the online publication of an abstract (Abstract #298561) reporting phase IIa data from this trial in the proceedings of the virtual annual meeting of American Society of Clinical Oncology 2020 (ASCO20).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top